Differences in pharmacotherapy and in glucose control of type 2 diabetes patients in two neighbouring towns: a longitudinal population‐based study

Olsson, Jonny; Lindberg, Gunnar; Göttsater, Mikael; Lindwall, K.; Sjöstrand, Å.; Tisell, Anders; Melander, Arne

doi:10.1046/j.1463-1326.2001.00110.x

Cited by 6 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Insulin was prescribed for 11·5% of the type 2 diabetic patients. This is higher than the 8% reported in Canada (33) and 9·4% in Spain (34) but less than the 20% reported in Sweden (35) and 23% in Denmark (36).…”

Section: Discussioncontrasting

confidence: 55%

Drug utilization of oral hypoglycemic agents in a university teaching hospital in India

Sultana

Kapur²,

Aqil

et al. 2010

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

This study strongly highlights the need for patient education or counselling on use of antidiabetic and concomitant drugs, monitoring of blood glucose and glycosylated haemoglobin (HbA1c) levels, diet control, and correction of diabetic complications. Metabolic control was poor and HbA1c monitoring was underutilized. Clinical monitoring of patients' adherence to prescribed treatments is recommended and measures should be taken to improve it.

show abstract

Section: Discussioncontrasting

confidence: 55%

Drug utilization of oral hypoglycemic agents in a university teaching hospital in India

Sultana

Kapur²,

Aqil

et al. 2010

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

show abstract

“…However, many subjects with type 2 diabetes may be undetected, and many detected subjects may be undertreated [3,4]. Moreover, several earlier studies indicate that the utilisation of AHGDs varies pronouncedly, both between and within countries, and even within counties [5][6][7][8][9][10][11][12][13][14][15]. A comparison of the Nordic countries in 1985 suggested that greater utilisation was associated with a higher degree of obesity and a higher prevalence of diabetes [8].…”

Section: Introductionmentioning

confidence: 99%

“…In addition, the countries with the highest utilisation also appeared to use higher mean doses of AHGDs. A later comparison of the diabetes populations in two Swedish neighbouring towns indicated that glucose control was better in the town in which AHGD use was more extensive [15]. Based on these findings, and as recent studies have revealed very large differences between European countries in terms of the utilisation of other drugs, such as antibiotics [16] and statins [17], the aim of the present study was to update and compare the utilisation of insulin and oral AHGDs in a number of European countries where such data were available.…”

Section: Introductionmentioning

confidence: 99%

Utilisation of antihyperglycaemic drugs in ten European countries: different developments and different levels

et al. 2006

Self Cite

View full text Add to dashboard Cite

Aims/hypothesis The aim of this study was to compare developments in the utilisation of antihyperglycaemic drugs (AHGDs) in ten European countries. Subjects and methods Data on the yearly utilisation of insulin and oral AHGDs were collected from public registers in Denmark, Finland, Norway, Sweden, Belgium, England, Germany, Italy, Portugal and Spain, and were expressed as defined daily doses per 1,000 inhabitants per day. Results Total AGHD utilisation increased everywhere, but at different rates and levels. Insulin utilisation doubled in England and Germany, but hardly changed in Belgium, Portugal or Italy. Sulfonylurea utilisation doubled in Spain, England and Denmark but was reduced in Germany and Sweden. Metformin utilisation increased greatly everywhere. There were two-to three-fold differences in AHGD utilisation even between neighbouring countries. In Finland, there were more users of both insulin (+120%) and oral AHGDs (+80%) than in Den- Diabetologia (2006) mark, and the daily oral AHGD doses were higher. In Denmark and Sweden, AHGD utilisation was equal in subjects aged <45 years, but in those ≥45 years of age, both insulin and oral AHGD utilisation were twice as high in Sweden. Conclusions/interpretation The ubiquitous increase in AHGD utilisation, particularly metformin, seems logical, considering the increasing prevalence of type 2 diabetes and the results of the UK Prospective Diabetes Study. However, the large differences even between neighbouring countries are more difficult to explain, and suggest different habits and attitudes in terms of screening and management of type 2 diabetes.

show abstract

Current Awareness

2002

Diabetes Metabolism Res

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of diabetes/metabolism. Each bibliography is divided into 17 sections: 1 Books, Reviews & Symposia; 2 General; 3 Genetics; 4 Epidemiology; 5 Immunology; 6 Prediction; 7 Prevention; 8 Intervention: a) General; b) Pharmacology; 9 Pathology: a) General; b) Cardiovascular; c) Neurological; d) Renal; 10 Endocrinology & Metabolism; 11 Nutrition; 12 Animal Studies; 13 Techniques. Within each section, articles are listed in alphabetical order with respect to author (8 Weeks journals ‐ Search completed at 19th Dec 2001)

show abstract

Differences in pharmacotherapy and in glucose control of type 2 diabetes patients in two neighbouring towns: a longitudinal population‐based study

Abstract: Glucose control in routine care was better when most patients were treated by a diabetes specialist and were exposed to more intense pharmacotherapy.

Cited by 6 publications

References 8 publications

Drug utilization of oral hypoglycemic agents in a university teaching hospital in India

Drug utilization of oral hypoglycemic agents in a university teaching hospital in India

Utilisation of antihyperglycaemic drugs in ten European countries: different developments and different levels

Current Awareness

Contact Info

Product

Resources

About